Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer
Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer
复制标题
DOI：
10.1371/journal.pone.0220456
复制
发表时间：
2019-08-08
期刊：
影响因子：
3.7
通讯作者：
Doak, Shareen H.
中科院分区：
文献类型：
--
作者：
Burnell, Stephanie E. A.;Spencer-Harty, Samantha;Doak, Shareen H.
前列腺癌是全球男性中诊断的第二大常见癌症;然而，很少有患者在其一生中受到临床显著疾病的影响。不幸的是，目前无法区分患有惰性疾病的患者和进展为侵袭性前列腺癌的患者，导致患者的过度治疗。因此，我们的目的是确定前列腺癌的生物标志物，可用于临床，以帮助诊断和预后。对前列腺癌标本进行免疫组织化学分析，Gleason评分范围。对样品进行染色并分析前列腺七跨膜上皮抗原（STEAP）-1、-2、-3、-4和二价金属转运蛋白1（DMT 1）蛋白的强度，以确定用于对可能发展为侵袭性前列腺癌的患者进行分类的合适生物标志物。此外，还分析了这些蛋白质，以确定是否能够使用Kaplan Meier分析预测未来的复发。生成的数据表明，STEAP 2的蛋白表达水平与Gleason评分显著相关;此外，STEAP 4是复发的显著预测因子。该数据表明，STEAP 2可能是与当前前列腺癌检测方法组合使用的潜在预后候选物，并且STEAP 4的存在可能是可能复发的指标。
Prostate cancer is the second most common cancer diagnosed in men worldwide; however, few patients are affected by clinically significant disease within their lifetime. Unfortunately, the means to discriminate between patients with indolent disease and those who progress to aggressive prostate cancer is currently unavailable, resulting in over-treatment of patients. We therefore aimed to determine biomarkers of prostate cancer that can be used in the clinic to aid the diagnosis and prognosis. Immunohistochemistry analysis was carried out on prostate cancer specimens with a range of Gleason scores. Samples were stained and analysed for intensity of the Seven Transmembrane Epithelial Antigen of the Prostate (STEAP)-1, -2, -3, -4 and the Divalent Metal Transporter 1 (DMT1) proteins to determine suitable biomarkers for classification of patients likely to develop aggressive prostate cancer. Additionally, these proteins were also analysed to determine whether any would be able to predict future relapse using Kaplan Meier analysis. Data generated demonstrated that the protein expression levels of STEAP2 correlated significantly with Gleason score; furthermore, STEAP4 was a significant predictor of relapse. This data indicates that STEAP2 could be potential prognostic candidate for use in combination with the current prostate cancer detection methods and the presence of STEAP4 could be an indicator of possible relapse.